002412.SZ
Hunan Hansen Pharmaceutical Co. Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 11.21
+10.01%Aug 27, 2026, 08:47 UTC
Hansen Pharmaceutical completed the change registration of its Drug Manufacturing License, obtaining a new license from the Hunan Provincial Drug Administration, valid until November 6, 2030.
Source:Aug 25, 2026, 05:56 UTC
On August 25, 2026, the Shenwan primary industry pharmaceutical and biological sector rose 1.22% to 7852.96 points at midday, with multiple stocks hitting the daily limit, including Transgen Life, Jiheng Pharmaceutical, Weiguang Biological, Huasen Pharmaceutical, Hansen Pharmaceutical, and Hainan Haiyao.
Source:Aug 24, 2026, 09:01 UTC
Hansen Pharmaceutical released its 2026 semi-annual report, reporting revenue of 476 million yuan, down 6.42% year-on-year, and net profit attributable to shareholders of 107 million yuan, up 55.52% year-on-year.
Source:Jul 28, 2026, 10:54 UTC
Hansen Pharmaceutical plans to terminate its 173-mu development land investment project for expanding basic drug production lines, originally initiated in 2011 and re-contracted in 2022, due to industry changes and land listing issues, with no material adverse impact on operations.
Source: